Experimental donor cell therapy shows promise for tough blood cancers
NCT ID NCT04620681
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 34 times
Summary
This study tested a new treatment for people with myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (AML) who had not responded to standard therapy. The treatment involved giving patients chemotherapy followed by an infusion of donor immune cells that had been specially processed to remove certain cells (CD8-depleted). The main goal was to find the safest dose of these donor cells. The trial enrolled 19 participants and has been completed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD8-depleted donor immune cells (lymphocytes) given after chemotherapy
What this could lead to
If it works, this could offer a new treatment option for people with MDS or secondary AML who have not responded to standard therapies.
What could go wrong
This is a small, early-phase trial with only 19 participants, so results may not apply to everyone. The treatment involves donor cells and chemotherapy, which carry risks of infection, graft-versus-host disease, and other serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.